submit url • add directory • hospitals
Today's News:
Pharma Industry / Biotech Industry News From Medical News Today
Circassia Announces Successful Results From Phase II Clinical Study Of ToleroMune(R) Cat Allergy Therapy
Sat, 21 Nov 2009 01:00:00 -0800
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced positive results from a recently completed phase II clinical study of its ToleroMune(R) cat allergy therapy, which successfully identified the optimal dosing regimens to progress into late-stage development.
Dendreon Receives FDA Acknowledgement Of Complete Response
Sat, 21 Nov 2009 01:00:00 -0800
Dendreon Corporation (Nasdaq: DNDN) announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA.
Positive Results From Chronic Study With Bayer's Rivaroxaban Will Be Presented As A Late Breaker At ASH 2009
Sat, 21 Nov 2009 01:00:00 -0800
Findings from the Phase III EINSTEIN-Extension study will be presented in the Late Breaking Abstract Session on December 8, 2009, (7:30 am EST, Hall F, Ernest N. Morial Convention Center) at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.
ICT Fails To Accelerate Drug Approvals
Sat, 21 Nov 2009 00:00:00 -0800
Drug approvals are taking just as long as they ever did despite increased expenditure on new information technology at the Food and drug Administration. So says a statistical analysis of approval intervals from 1997 to 2006, published in the International Journal of Electronic Healthcare.
Daschle Still Making Voice Heard On Health Care
Fri, 20 Nov 2009 05:00:00 -0800
The Hill reports that former Senate Majority Leader Tom Daschle helped Obama Administration officials strategize to win health care reform votes from Senators on Capitol Hill Wednesday.
Lawmakers Call For Inquiry Into Pharmaceutical Company Price Hikes
Fri, 20 Nov 2009 05:00:00 -0800
Reuters: "Congressional Democrats are seeking government investigations into recent price increases of brand-name prescription drugs, as Congress finalizes an overhaul of the healthcare system.
Annals of Pharmacotherapy PAP Articles
Healthcare Reform 2009 and Its Implications for Pharmacists (December)
Matzke, G. R The US healthcare system has been widely criticized by many and praised by others for many reasons that are not mutually exclusive. There is no doubt that, compared with our peer industrialized countries, the US ranks near the bottom in many of the benchmark criteria such as life expectancy, infant mortality, and mortality of the population that is amenable to health care. Despite these shortcomings, the US has been a major innovator in healthcare technology including the development of biological and pharmacological drugs. The shortcomings of our system are often focused on the fact that a significant portion of the population lacks access to these cutting-edge resources and therapies. In this commentary, the healthcare reform proposals that have been introduced in 2008-2009, with a focus on the 3 leading plans that have been put forward by the House of Representatives and Senate, are reviewed. The inclusion of pharmacist-delivered medication therapy management (MTM) as well as medication reconciliation (MedRec) is specifically stated in 2 of the 3 plans. Integrated care delivery models (ie, community health teams, or "medical homes") are also directed to provide MedRec and MTM during transitions of care. Finally, in the Senate Health, Education, Labor, and Pensions language, there is a directive that health insurers implement a payment schedule for MTM and care compliance. The many other ways in which each of these evolving reform proposals may impact pharmacists and the care they deliver to their communities are also highlighted.
Seasonal, Avian, and Novel H1N1 Influenza: Prevention and Treatment Modalities (December)
Sym, D., Patel, P. N, El-Chaar, G. M OBJECTIVE: To review the pathophysiology, pandemics/epidemics, transmissibility, clinical presentation, treatment, prevention/immunization, and resistance associated with seasonal, avian, and swine influenza. DATA SOURCES: Literature was obtained from MEDLINE (1966-October 2009) and International Pharmaceutical Abstracts (1971-October 2009) using the search terms influenza, seasonal influenza, avian influenza, swine influenza, H1N1, novel H1N1, H3N2, and H5N1. STUDY SELECTION AND DATA EXTRACTION: Available English-language articles were reviewed, along with information obtained from the Centers for Disease Control and Prevention, the Food and Drug Administration, and the World Health Organization. DATA SYNTHESIS: The influenza virus has caused disease in birds, swine, and humans for many centuries. Pandemics and epidemics have occurred throughout history and reports of new strains continue to emerge. Two major surface antigenic glycoproteins, hemagglutinin and neuraminidase, have various subtypes, resulting in numerous combinations of these proteins. For example, combinations occur when an influenza strain from a bird "mixes" with a strain from a human. This mixing occurs in a host, often in pigs, resulting in a new strain. This new strain can cause pandemics since people have no immunity to the new strain. An H1N1 subtype pandemic occurred in 1918, causing millions of deaths. Simultaneously, veterinary reports of "influenza" in pigs also emerged. It is postulated that humans infected pigs with this H1N1 virus. H1N1 reappeared in humans in 1976, and more recently in 2009. Other pandemics have occurred with H2N2 and H3N2 strains. In 1997, strain H5N1, which usually causes disease in fowl, was able to infect humans. CONCLUSIONS: Influenza subtypes continue to change, causing disease in animals and humans. Utilization of immunization and antiviral treatment options are available to prevent, treat, and contain the spread of this infection.
Clinical Handbook of Psychotropic Drugs, 18th Revised Edition (December)
Ray, S. M, McMillen, J. C
Does Simvastatin Cause More Myotoxicity Compared with Other Statins? (December)
Backes, J. M, Howard, P. A, Ruisinger, J. F, Moriarty, P. M OBJECTIVE: To review the literature regarding statins and myotoxicity and evaluate these data to determine whether incidence rates are higher with simvastatin. DATA SOURCES: Literature was identified from a search of MEDLINE (1966- August 2009) and International Pharmaceutical Abstracts (1970-August 2009), as well as references of selected articles. Key search terms included the names of individual statins, rhabdomyolysis, myopathy, myalgia, myotoxicity, statins, and drug interactions. STUDY SELECTION AND DATA EXTRACTION: All English-language articles discussing statin-related myotoxicity and relevant drug interactions that involved human subjects were examined. DATA SYNTHESIS: Simvastatin is a commonly prescribed, moderately potent statin. Recent evidence suggests that the risk of severe muscle toxicity with simvastatin may be higher than that with other statins, particularly when used in combination with cytochrome P450 isoenzyme inhibitors. However, the lack of direct comparative clinical trials assessing the risk of myotoxicity among the statins in equivalent doses precludes definitive conclusions. Data sources examining low-to-moderate doses of simvastatin suggest that myotoxicity with this agent is infrequent, with rates similar to those seen with other statins. Conversely, findings from clinical trials using the maximum daily dose (80 mg) and a clinical trials database of varying doses of simvastatin suggest a possible increase in rates of myotoxicity with the 80-mg dose compared with lower doses and a higher incidence rate when compared with maximum doses of other statins. CONCLUSIONS: Overall, the rates of severe myotoxicity with all statins are low, especially with low-to-moderate doses. However, recent trials for those using simvastatin 80 mg daily suggest a higher incidence of myotoxicity compared with maximum approved doses of other statins. Practitioners should be aware of these possible risks and individualize therapy to limit myotoxicity.
Factors Associated with Multiple Medication Use in Different Age Groups(December)
Moen, J., Antonov, K., Larsson, C. A, Lindblad, U., Nilsson, J L. G, Rastam, L., Ring, L. BACKGROUND: Multiple medicine use among elderly persons is likely to be the result of treatment regimens developed over a long period of time. By learning more about how multiple medication use develops, the quality of prescribing may be improved across the adult lifespan. OBJECTIVE: To describe patterns of multiple medicine use in the general Swedish population and its association with sociodemographic, lifestyle, and health status factors. METHODS: Data from a cross-sectional population health survey collected during 2001-2005 from 2816 randomly selected Swedish residents (age 30-75 y; response rate 76%) were analyzed. Multiple medicine use was restricted to prescription drugs and defined as the 75th percentile; that is, the 25% of the study group using the highest number of drugs per individual. RESULTS: Seventy-one percent of the respondents used some kind of drug, 51.5% used one or more prescription drug, 38.4% used one or more over-the-counter (OTC) medication, and 8.3% used one or more herbal preparation. The cutoff amounts defining multiple medicine use were: 2 or more medications for 30- to 49-year-olds, 3 or more for 50- to 64-year-olds, and 5 or more for 65- to 75- year-olds. No association between use of multiple medicines and use of OTC drugs or herbal preparations was found. When drugs were classified into therapeutic subgroups, 76.3% of those aged 30-49 years, 97.9% of those aged 50-64 years, and 100% of those aged 65-75 years were taking a unique combination of drugs. Multivariate analyses showed that diabetes and poor self-rated health were associated with multiple medicine use in all age cohorts. Female sex and hypertension were associated with multiple medicine use among those aged 30-49 and 50-64 years, current smoking among those aged 50-64 years, and obesity among those aged 65-75 years. CONCLUSIONS: Multiple medicine use was associated with morbidity and poor self-rated health across all age groups. The vast majority of users of multiple drugs are taking a unique combination of medications.
Propylene Glycol Accumulation in Critically Ill Patients Receiving Continuous Intravenous Lorazepam Infusions(December)
Horinek, E. L, Kiser, T. H, Fish, D. N, MacLaren, R. BACKGROUND: Lorazepam is recommended by the Society of Critical Care Medicine as the preferred agent for sedation of critically ill patients. Intravenous lorazepam contains propylene glycol, which has been associated with toxicity when high doses of lorazepam are administered. OBJECTIVE: To evaluate the accumulation of propylene glycol in critically ill patients receiving lorazepam by continuous infusion and determine factors associated with propylene glycol concentration. METHODS: A 6-month, retrospective, safety assessment was conducted of adults admitted to the medical intensive care unit who were receiving lorazepam by continuous infusion for 12 hours or more. Propylene glycol serum concentrations were obtained 24-48 hours after continuous-infusion lorazepam was initiated and every 3-5 days thereafter. Propylene glycol accumulation was defined as concentrations of 25 mg/dL or more. Groups with and without propylene glycol accumulation were compared and factors associated with propylene glycol concentration were determined using multivariate correlation regression analyses. RESULTS: Forty-eight propylene glycol serum samples were obtained from 33 patients. Fourteen (42%) patients had propylene glycol accumulation, representing 23 (48%) serum samples. Univariate analyses showed the following factors were related to propylene glycol accumulation: baseline renal dysfunction, presence of alcohol withdrawal, sex, age, Acute Physiology and Chronic Health Evaluation (APACHE II) score, rate of lorazepam continuous infusion, and 24-hour lorazepam dose. Multivariate linear regression modeling demonstrated that propylene glycol concentration was strongly associated with the continuous infusion rate and 24-hour dose (adjusted r2 ≥0.77; p < 0.001). Independent correlation analyses showed that these 2 variables were so strongly associated with propylene glycol concentration (r2 ≥0.71; p < 0.001) that they alone predicted propylene glycol concentration. Seven (21%) patients developed renal dysfunction after continuous-infusion lorazepam was initiated, but associated causes were indeterminable. Other possible propylene glycol-associated adverse effects were not observed. CONCLUSIONS: The continuous infusion rate and cumulative 24-hour lorazepam dose are strongly associated with and independently predict propylene glycol concentrations. Despite the absence of confirmed propylene glycol-associated adverse effects, clinicians should be aware that propylene glycol accumulation may occur with continuous-infusion lorazepam.
Clinical Pharmacology & Therapeutics - Issue - nature.com science feeds
In This Issue
Mon, 16 Nov 2009 00:00:00 -0000
In This Issue Clinical Pharmacology & Therapeutics 86, 571 (December 2009). doi:10.1038/clpt.2009.229
Neonatal Pharmacology: Rational Therapeutics for the Most Vulnerable
L JamesS Ito Mon, 16 Nov 2009 00:00:00 -0000
Neonatal Pharmacology: Rational Therapeutics for the Most Vulnerable Clinical Pharmacology & Therapeutics 86, 573 (December 2009). doi:10.1038/clpt.2009.212 Authors: L James & S Ito
Highlights
Mon, 16 Nov 2009 00:00:00 -0000
Highlights Clinical Pharmacology & Therapeutics 86, 578 (December 2009). doi:10.1038/clpt.2009.230 Author:
ASCPT News
Mon, 16 Nov 2009 00:00:00 -0000
ASCPT News Clinical Pharmacology & Therapeutics 86, 580 (December 2009). doi:10.1038/clpt.2009.220
Pediatric Drug Development: Concepts and Applications
S M MacLeod Mon, 16 Nov 2009 00:00:00 -0000
Pediatric Drug Development: Concepts and Applications Clinical Pharmacology & Therapeutics 86, 583 (December 2009). doi:10.1038/clpt.2009.192 Author: S M MacLeod
Clinical Trials in Neonates: A Therapeutic Imperative
R M WardS E Kern Mon, 16 Nov 2009 00:00:00 -0000
Clinical Trials in Neonates: A Therapeutic Imperative Clinical Pharmacology & Therapeutics 86, 585 (December 2009). doi:10.1038/clpt.2009.207 Authors: R M Ward & S E Kern
Circassia Announces Successful Results From Phase II Clinical Study Of ToleroMune(R) Cat Allergy Therapy
Sat, 21 Nov 2009 01:00:00 -0800
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced positive results from a recently completed phase II clinical study of its ToleroMune(R) cat allergy therapy, which successfully identified the optimal dosing regimens to progress into late-stage development.
Dendreon Receives FDA Acknowledgement Of Complete Response
Sat, 21 Nov 2009 01:00:00 -0800
Dendreon Corporation (Nasdaq: DNDN) announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA.
Positive Results From Chronic Study With Bayer's Rivaroxaban Will Be Presented As A Late Breaker At ASH 2009
Sat, 21 Nov 2009 01:00:00 -0800
Findings from the Phase III EINSTEIN-Extension study will be presented in the Late Breaking Abstract Session on December 8, 2009, (7:30 am EST, Hall F, Ernest N. Morial Convention Center) at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.
ICT Fails To Accelerate Drug Approvals
Sat, 21 Nov 2009 00:00:00 -0800
Drug approvals are taking just as long as they ever did despite increased expenditure on new information technology at the Food and drug Administration. So says a statistical analysis of approval intervals from 1997 to 2006, published in the International Journal of Electronic Healthcare.
Daschle Still Making Voice Heard On Health Care
Fri, 20 Nov 2009 05:00:00 -0800
The Hill reports that former Senate Majority Leader Tom Daschle helped Obama Administration officials strategize to win health care reform votes from Senators on Capitol Hill Wednesday.
Lawmakers Call For Inquiry Into Pharmaceutical Company Price Hikes
Fri, 20 Nov 2009 05:00:00 -0800
Reuters: "Congressional Democrats are seeking government investigations into recent price increases of brand-name prescription drugs, as Congress finalizes an overhaul of the healthcare system.
Annals of Pharmacotherapy PAP Articles
Healthcare Reform 2009 and Its Implications for Pharmacists (December)
Matzke, G. R The US healthcare system has been widely criticized by many and praised by others for many reasons that are not mutually exclusive. There is no doubt that, compared with our peer industrialized countries, the US ranks near the bottom in many of the benchmark criteria such as life expectancy, infant mortality, and mortality of the population that is amenable to health care. Despite these shortcomings, the US has been a major innovator in healthcare technology including the development of biological and pharmacological drugs. The shortcomings of our system are often focused on the fact that a significant portion of the population lacks access to these cutting-edge resources and therapies. In this commentary, the healthcare reform proposals that have been introduced in 2008-2009, with a focus on the 3 leading plans that have been put forward by the House of Representatives and Senate, are reviewed. The inclusion of pharmacist-delivered medication therapy management (MTM) as well as medication reconciliation (MedRec) is specifically stated in 2 of the 3 plans. Integrated care delivery models (ie, community health teams, or "medical homes") are also directed to provide MedRec and MTM during transitions of care. Finally, in the Senate Health, Education, Labor, and Pensions language, there is a directive that health insurers implement a payment schedule for MTM and care compliance. The many other ways in which each of these evolving reform proposals may impact pharmacists and the care they deliver to their communities are also highlighted.
Seasonal, Avian, and Novel H1N1 Influenza: Prevention and Treatment Modalities (December)
Sym, D., Patel, P. N, El-Chaar, G. M OBJECTIVE: To review the pathophysiology, pandemics/epidemics, transmissibility, clinical presentation, treatment, prevention/immunization, and resistance associated with seasonal, avian, and swine influenza. DATA SOURCES: Literature was obtained from MEDLINE (1966-October 2009) and International Pharmaceutical Abstracts (1971-October 2009) using the search terms influenza, seasonal influenza, avian influenza, swine influenza, H1N1, novel H1N1, H3N2, and H5N1. STUDY SELECTION AND DATA EXTRACTION: Available English-language articles were reviewed, along with information obtained from the Centers for Disease Control and Prevention, the Food and Drug Administration, and the World Health Organization. DATA SYNTHESIS: The influenza virus has caused disease in birds, swine, and humans for many centuries. Pandemics and epidemics have occurred throughout history and reports of new strains continue to emerge. Two major surface antigenic glycoproteins, hemagglutinin and neuraminidase, have various subtypes, resulting in numerous combinations of these proteins. For example, combinations occur when an influenza strain from a bird "mixes" with a strain from a human. This mixing occurs in a host, often in pigs, resulting in a new strain. This new strain can cause pandemics since people have no immunity to the new strain. An H1N1 subtype pandemic occurred in 1918, causing millions of deaths. Simultaneously, veterinary reports of "influenza" in pigs also emerged. It is postulated that humans infected pigs with this H1N1 virus. H1N1 reappeared in humans in 1976, and more recently in 2009. Other pandemics have occurred with H2N2 and H3N2 strains. In 1997, strain H5N1, which usually causes disease in fowl, was able to infect humans. CONCLUSIONS: Influenza subtypes continue to change, causing disease in animals and humans. Utilization of immunization and antiviral treatment options are available to prevent, treat, and contain the spread of this infection.
Clinical Handbook of Psychotropic Drugs, 18th Revised Edition (December)
Ray, S. M, McMillen, J. C
Does Simvastatin Cause More Myotoxicity Compared with Other Statins? (December)
Backes, J. M, Howard, P. A, Ruisinger, J. F, Moriarty, P. M OBJECTIVE: To review the literature regarding statins and myotoxicity and evaluate these data to determine whether incidence rates are higher with simvastatin. DATA SOURCES: Literature was identified from a search of MEDLINE (1966- August 2009) and International Pharmaceutical Abstracts (1970-August 2009), as well as references of selected articles. Key search terms included the names of individual statins, rhabdomyolysis, myopathy, myalgia, myotoxicity, statins, and drug interactions. STUDY SELECTION AND DATA EXTRACTION: All English-language articles discussing statin-related myotoxicity and relevant drug interactions that involved human subjects were examined. DATA SYNTHESIS: Simvastatin is a commonly prescribed, moderately potent statin. Recent evidence suggests that the risk of severe muscle toxicity with simvastatin may be higher than that with other statins, particularly when used in combination with cytochrome P450 isoenzyme inhibitors. However, the lack of direct comparative clinical trials assessing the risk of myotoxicity among the statins in equivalent doses precludes definitive conclusions. Data sources examining low-to-moderate doses of simvastatin suggest that myotoxicity with this agent is infrequent, with rates similar to those seen with other statins. Conversely, findings from clinical trials using the maximum daily dose (80 mg) and a clinical trials database of varying doses of simvastatin suggest a possible increase in rates of myotoxicity with the 80-mg dose compared with lower doses and a higher incidence rate when compared with maximum doses of other statins. CONCLUSIONS: Overall, the rates of severe myotoxicity with all statins are low, especially with low-to-moderate doses. However, recent trials for those using simvastatin 80 mg daily suggest a higher incidence of myotoxicity compared with maximum approved doses of other statins. Practitioners should be aware of these possible risks and individualize therapy to limit myotoxicity.
Factors Associated with Multiple Medication Use in Different Age Groups(December)
Moen, J., Antonov, K., Larsson, C. A, Lindblad, U., Nilsson, J L. G, Rastam, L., Ring, L. BACKGROUND: Multiple medicine use among elderly persons is likely to be the result of treatment regimens developed over a long period of time. By learning more about how multiple medication use develops, the quality of prescribing may be improved across the adult lifespan. OBJECTIVE: To describe patterns of multiple medicine use in the general Swedish population and its association with sociodemographic, lifestyle, and health status factors. METHODS: Data from a cross-sectional population health survey collected during 2001-2005 from 2816 randomly selected Swedish residents (age 30-75 y; response rate 76%) were analyzed. Multiple medicine use was restricted to prescription drugs and defined as the 75th percentile; that is, the 25% of the study group using the highest number of drugs per individual. RESULTS: Seventy-one percent of the respondents used some kind of drug, 51.5% used one or more prescription drug, 38.4% used one or more over-the-counter (OTC) medication, and 8.3% used one or more herbal preparation. The cutoff amounts defining multiple medicine use were: 2 or more medications for 30- to 49-year-olds, 3 or more for 50- to 64-year-olds, and 5 or more for 65- to 75- year-olds. No association between use of multiple medicines and use of OTC drugs or herbal preparations was found. When drugs were classified into therapeutic subgroups, 76.3% of those aged 30-49 years, 97.9% of those aged 50-64 years, and 100% of those aged 65-75 years were taking a unique combination of drugs. Multivariate analyses showed that diabetes and poor self-rated health were associated with multiple medicine use in all age cohorts. Female sex and hypertension were associated with multiple medicine use among those aged 30-49 and 50-64 years, current smoking among those aged 50-64 years, and obesity among those aged 65-75 years. CONCLUSIONS: Multiple medicine use was associated with morbidity and poor self-rated health across all age groups. The vast majority of users of multiple drugs are taking a unique combination of medications.
Propylene Glycol Accumulation in Critically Ill Patients Receiving Continuous Intravenous Lorazepam Infusions(December)
Horinek, E. L, Kiser, T. H, Fish, D. N, MacLaren, R. BACKGROUND: Lorazepam is recommended by the Society of Critical Care Medicine as the preferred agent for sedation of critically ill patients. Intravenous lorazepam contains propylene glycol, which has been associated with toxicity when high doses of lorazepam are administered. OBJECTIVE: To evaluate the accumulation of propylene glycol in critically ill patients receiving lorazepam by continuous infusion and determine factors associated with propylene glycol concentration. METHODS: A 6-month, retrospective, safety assessment was conducted of adults admitted to the medical intensive care unit who were receiving lorazepam by continuous infusion for 12 hours or more. Propylene glycol serum concentrations were obtained 24-48 hours after continuous-infusion lorazepam was initiated and every 3-5 days thereafter. Propylene glycol accumulation was defined as concentrations of 25 mg/dL or more. Groups with and without propylene glycol accumulation were compared and factors associated with propylene glycol concentration were determined using multivariate correlation regression analyses. RESULTS: Forty-eight propylene glycol serum samples were obtained from 33 patients. Fourteen (42%) patients had propylene glycol accumulation, representing 23 (48%) serum samples. Univariate analyses showed the following factors were related to propylene glycol accumulation: baseline renal dysfunction, presence of alcohol withdrawal, sex, age, Acute Physiology and Chronic Health Evaluation (APACHE II) score, rate of lorazepam continuous infusion, and 24-hour lorazepam dose. Multivariate linear regression modeling demonstrated that propylene glycol concentration was strongly associated with the continuous infusion rate and 24-hour dose (adjusted r2 ≥0.77; p < 0.001). Independent correlation analyses showed that these 2 variables were so strongly associated with propylene glycol concentration (r2 ≥0.71; p < 0.001) that they alone predicted propylene glycol concentration. Seven (21%) patients developed renal dysfunction after continuous-infusion lorazepam was initiated, but associated causes were indeterminable. Other possible propylene glycol-associated adverse effects were not observed. CONCLUSIONS: The continuous infusion rate and cumulative 24-hour lorazepam dose are strongly associated with and independently predict propylene glycol concentrations. Despite the absence of confirmed propylene glycol-associated adverse effects, clinicians should be aware that propylene glycol accumulation may occur with continuous-infusion lorazepam.
Clinical Pharmacology & Therapeutics - Issue - nature.com science feeds
In This Issue
Mon, 16 Nov 2009 00:00:00 -0000
In This Issue Clinical Pharmacology & Therapeutics 86, 571 (December 2009). doi:10.1038/clpt.2009.229
Neonatal Pharmacology: Rational Therapeutics for the Most Vulnerable
L JamesS Ito Mon, 16 Nov 2009 00:00:00 -0000
Neonatal Pharmacology: Rational Therapeutics for the Most Vulnerable Clinical Pharmacology & Therapeutics 86, 573 (December 2009). doi:10.1038/clpt.2009.212 Authors: L James & S Ito
Highlights
Mon, 16 Nov 2009 00:00:00 -0000
Highlights Clinical Pharmacology & Therapeutics 86, 578 (December 2009). doi:10.1038/clpt.2009.230 Author:
ASCPT News
Mon, 16 Nov 2009 00:00:00 -0000
ASCPT News Clinical Pharmacology & Therapeutics 86, 580 (December 2009). doi:10.1038/clpt.2009.220
Pediatric Drug Development: Concepts and Applications
S M MacLeod Mon, 16 Nov 2009 00:00:00 -0000
Pediatric Drug Development: Concepts and Applications Clinical Pharmacology & Therapeutics 86, 583 (December 2009). doi:10.1038/clpt.2009.192 Author: S M MacLeod
Clinical Trials in Neonates: A Therapeutic Imperative
R M WardS E Kern Mon, 16 Nov 2009 00:00:00 -0000
Clinical Trials in Neonates: A Therapeutic Imperative Clinical Pharmacology & Therapeutics 86, 585 (December 2009). doi:10.1038/clpt.2009.207 Authors: R M Ward & S E Kern
Pharmacology RSS feed 
Sites:
Annual PET Pharmacokinetic Course: Course on application of PET to pharmacokinetics, open to professionals in a wide variety of fields. Held at different locations around the world, next is June 2003 in Montreal, Canada.Cytochrome P450: Identification of a novel transcriptional silencer in the protein-coding region of the human cytochrome P450 2C9 gene.
Department of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico: Department of Pharmacology and Toxicology; University of Puerto Rico; Information about the department and the graduate program in Pharmacology and Toxicology., Department of Pharmacology and Toxicology; University of Puerto Rico; Information about the department and the graduate program in Pharm...
Department of Preclinical and Clinical Pharmacology, University of Florence, Italy: Information on research activities in Pharmacology.
Dissolution Solutions Network: Dissolution Solutions Network: Pharmaceutical scientists providing real answers for one another. The latest news, forum, blog and more...
DrugInfo. Searching the Web for Drug Information: A personal Website based on 30-years experience in pharmacology. Provides help to Web browsers in locating the most relevant drug information on the Web.
Elliot Brown Consulting: MedDRA training, products and pharmacovigilance by Dr Elliot Brown Consultancy.Pharmaceutical regulatory affairs, Adverse experiences, adverse events, drug safety surveillance, post marketing surveillance, EMEA, SPMP, MCA ,
FDA Drug Approvals List: Updated weekly as a service by CDER's Division of Data Management and Services.
Institute of Pharmacology University of Bern Switzerland: Information about the institute, its history, research areas and staff.
Institute of Pharmacology, Polish Academy of Sciences: Information about the Institute and its neuropharmacological research, including psychotropic drugs.
Laboratory of Pulmonary Pharmacology: research in human vascular pharmacology, reactivity of bronchial and vascular tissues, role of the eicosanoids and the cholinergic system
New York University Department of Pharmacology: Teaching of medical and graduate students, with research programs in normal growth and differentiation, development and pathology of the nervous system, and mechanisms of normal and abnormal functions of several key hormones.
Novartis Pharma: Here you'll find expert information about diseases, treatments and the full Novartis US product line, and an inside look at where we're headed.
Optimizing a Unimodal Response Function for Binary Variables: Adaptive designs for optimizing a unimodal response function for binary variables.
Ottosen Site for Drug Safety and Pharmacovigilance: Information about drug safety and clinical studies. Includes discussion forum, news and practical information about issues like safety reporting, licensing, contracts, PSUR, E2B, electronic submission.
Pharmacology and Legal Drugs - About.com: Search the power of About's network of topics
Pharmacology-Info.com: Information about pharmacology, toxicology, getting a new drug to market, and FDA approval.
SMR's Case Histories of Drug Discovery: Drug symposium organized by Society for Medicines Research, drug discovery of infliximab, zanamivir, olanzapine, alosetron, leflunomide and celecoxib.
Social Audit - the Antidepressant Web: social audit
The Lycaeum: An Entheogenic Database: The Lycaeum features an entheogen information database, drug experience archive with over 700 reports, search engine which spiders several major drug information sites, psychedelic graphics, transcribed books, community, software, audio, hosted sites, and much more.
The Ones That Stain Blue: Dr. Albert Hofmann
The Virtual Clinical Pharmacologist: Development of inpatient and outpatient anticoagulation and clinical pharmacology services. In conjunction with this we offer several multi-media CD rom products to assist the user in the development of these services. On line lectures are available .
TICTAC: The CD-ROM for drug identification of tablets & capsules
Toxicology-Info.com: Information on toxicology, drug interactions, toxicity and adverse reactions. Part of the ALtruis Biomedical Network.
University of Colorado Health Sciences Center - Department of Pharmacology: Department of Pharmacology and Graduate Program in Pharmacology at the University of Colorado Health Sciences Center at Denver and information about our pharmacology graduate program, curriculum, and research activities in the Pharmacology department. Research interests include: bioinformatics, m...
This directory is based on the Open Directory and may have been modified
